NCT02257450

Brief Summary

This research focuses on the prevalence of Primary Aldosteronism in the Malaysian adult population.

Trial Health

35
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
2,500

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Oct 2014

Typical duration for all trials

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

October 1, 2014

Completed
1 day until next milestone

First Submitted

Initial submission to the registry

October 2, 2014

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 6, 2014

Completed
2.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2017

Completed
Last Updated

October 18, 2016

Status Verified

October 1, 2016

Enrollment Period

2.7 years

First QC Date

October 2, 2014

Last Update Submit

October 17, 2016

Conditions

Primary Aldosteronism

Keywords

Primary AldosteronismHyperaldosteronism

Outcome Measures

Primary Outcomes (1)

  • Aldosterone-Renin Ratio

    Aldosterone-renin ratio of respondent at the time of sampling

    Day 0

Secondary Outcomes (2)

  • Level of Inflammatory Markers

    Day 0

  • Level of cardiovascular markers

    Day 0

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Malaysian adult population

You may qualify if:

  • years old and above
  • Malaysian citizen
  • Consent given

You may not qualify if:

  • Those who refused consent

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Biospecimen

Retention: SAMPLES WITHOUT DNA

Serum, plasma

MeSH Terms

Conditions

Hyperaldosteronism

Condition Hierarchy (Ancestors)

Adrenocortical HyperfunctionAdrenal Gland DiseasesEndocrine System Diseases

Study Officials

  • Nor Azmi Kamaruddin, FACE

    Malaysian Endocrine and Metabolic Society

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
ECOLOGIC OR COMMUNITY
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assist Prof

Study Record Dates

First Submitted

October 2, 2014

First Posted

October 6, 2014

Study Start

October 1, 2014

Primary Completion

June 1, 2017

Study Completion

June 1, 2017

Last Updated

October 18, 2016

Record last verified: 2016-10